Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Alzheimer’s Disease
Advertisement
Fujirebio Launches Automated pTau217 CSF Assay for Alzheimer’s Research
Tokyo, Japan – January 28, 2026 – Fujirebio, a global leader in in vitro diagnostics and part of H.U....
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
Medicare Expands Access to Early Alzheimer’s Therapies
FAIRFAX, Va., January 22, 2026 — Re:Cognition Health announced that Medicare coverage is now available for FDA-approved amyloid-targeting therapies...
Finger-Prick Blood Test Could Enable Early Alzheimer’s Diagnosis
London, January 19, 2026 — Scientists from a major international collaboration led by LifeArc and the Global Alzheimer’s Platform...
Advertisements
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Zervimesine Phase 3 Plan Advances Alzheimer’s Drug Strategy
Purchase, N.Y. — December 1, 2025 — Cognition Therapeutics has unveiled its Phase 3 registrational plan for Zervimesine (CT1812)...
Eisai Files NDA in Japan for Subcutaneous Leqembi to Expand Alzheimer’s Access
TOKYO & STOCKHOLM — November 28, 2025. Eisai, in partnership with BioArctic, has submitted a New Drug Application (NDA)...
Lighthouse to Present New Alzheimer’s Data on LHP588 at CTAD 2025
Boston, Massachusetts, November 26, 2025 — Lighthouse Pharmaceuticals announced that it will present new clinical and mechanistic updates for...
Labcorp Expands Alzheimer’s Detection with FDA-Cleared Test
BURLINGTON, N.C. – October 23, 2025 Labcorp (NYSE: LH), a global leader in laboratory diagnostics, announced it will soon...
Advertisement
